期刊文献+

卡培他滨联合调强放疗治疗乳腺癌肝转移的疗效观察 被引量:2

Clinical observation of capecitabine combined with intensity-modulated radiotherapy in the treatment of liver metastasis of breast cancer
下载PDF
导出
摘要 目的探讨卡培他滨联合调强放疗(intensity modulated raduation therapy,IMRT)并序贯卡培他滨治疗乳腺癌肝转移的疗效和不良反应。方法将52例乳腺癌肝转移患者分为卡培他滨联合放疗组27例和卡培他滨治疗组25例。卡培他滨联合放疗组肝转移灶行IMRT,6 MV-X线照射,以95%剂量曲线包绕99%计划靶区,常规分割,2 Gy/次,1次/d,5次/周,共4~6周,同时给予卡培他滨1 250 mg/m^2,2次/d口服同步化疗,放疗结束后给予卡培他滨2 510 mg/m^2,2次/d口服,21 d为1个周期。卡培他滨治疗组仅给予卡培他滨2 510 mg/m^2,2次/d口服,21 d为1个周期。比较两组疗效及不良反应。结果卡培他滨联合放疗组和卡培他滨治疗组有效率(RR)分别为74.1%和44%,肿瘤控制率分别为92.6%和68%,两组比较差异均有统计学意义(P<0.05);中位缓解时间分别为13.6个月和8.9个月,中位生存时间分别为17.4个月和11.7个月,1年生存率分别为85.2%和56.0%(P<0.05),2年生存率分别为40.7%和16.0%(P<0.05)。不良反应主要有中性粒细胞减少、胃肠道反应、肝功能损伤等,均以I级、Ⅱ级为主,卡培他滨联合放疗组I级、Ⅱ级不良反应发生率高于卡培他滨治疗组(P<0.05),但两组Ⅲ级、Ⅳ级不良反应发生率差异无统计学意义(P>0.05)。结论卡培他滨联合调强放疗并序贯卡培他滨治疗乳腺癌肝转移远期生存率优于单药卡培他滨维持治疗,不良反应可耐受,是一种有效的治疗方案。 Objective To study the efficacy and side effects of capecitabine combined with intensity-modulated radiation therapy (IMRT) against breast cancer that has metastasized to the liver. Methods A total of 52 patients with breast cancer that had metastasized to the liver were divided into 27 cases who were treated with capecitabine and radiation (capecitabine combined with radiotherapy group) and 25 cases who were treated with capecitabine only (capecitabine group). IMRT was performed on liver metastatic lesions of the capecitabine combined with radiotherapy group,and the 95% dose curve was wrapped around the 99% planned target,with conventional fractionation,2 Gy per time,5 times per week for 4-6 weeks;concurrently,capecitabine therapy (1250 mg/m2) was given 2 times/day orally. After radiotherapy,the patients were treated with capecitabine 2510 mg/m2(2 times/day orally) for a 21-day cycle. The control group was given only capecitabine at 2510 mg/m2(2 times/day orally) for a 21-day cycle. Results Total efficacy rate was 74.1% in the capecitabine combined with radiotherapy group,and 44% in the capecitabine group(P〈0.05). The tumor control probability (CR+PR+SD) was 92.6% in the capecitabine combined with radiotherapy group and 68% in the capecitabine group(P〈0.05). The median duration of response in the capecitabine combined with radiotherapy group was 13.6 months,compared to 8.9 months in the capecitabine group(P〈0.05). The median survival time in the capecitabine combined with radiotherapy group was 17.4 months and 11.7 months in the capecitabine group. Respective 1-year survival rates were 85.2% and 56.0%(P〈0.05);2-year survival rates were 40.7% and 16.0%(P〈0.05). Adverse reactions were mainly neutropenia,gastrointestinal reactions,and liver injury,and reactions were grade I and II. Conclusions Capecitabine combined with intensity-modulated radiotherapy for liver metastasis of breast cancer can improve patient survival rate,and adverse reactions can be tolerated.
出处 《中国癌症防治杂志》 CAS 2017年第1期65-68,共4页 CHINESE JOURNAL OF ONCOLOGY PREVENTION AND TREATMENT
基金 温岭市科技计划资助项目(2014C312080)
关键词 乳腺肿瘤 肝转移 卡培他滨 调强放疗 疗效 Breast neoplasms Liver metastasis Capecitabine Intensity-modulated radiotherapy Efficacy
  • 相关文献

参考文献3

二级参考文献76

  • 1王涛,江泽飞,宋三泰,申戈,张少华,张志强,曾敏.希罗达治疗乳腺癌所致手足综合征的发生规律及临床处理[J].癌症进展,2004,2(4):258-260. 被引量:67
  • 2胡夕春,郭海宜,杨新苗,李进.乳腺癌肝转移患者预后的多因素分析[J].中国癌症杂志,2005,15(5):438-441. 被引量:4
  • 3杨玲,李连弟,陈育德,D.M.Parkin.中国乳腺癌发病死亡趋势的估计与预测[J].中华肿瘤杂志,2006,28(6):438-440. 被引量:278
  • 4全国肿瘤防治研究办公室,全国肿瘤登记中心,卫生部疾病预防控制局.中国肿瘤死亡报告-全国第三次死因回顾抽样调查[M].北京:人民卫生出版社,2010,6.
  • 5STEWART B W, KLEIHUES P. World Cancer Report[M]. Lyon: IARC Press, 2003: 188-193.
  • 6FERLAY J, SHIN H R, BRAY F, et al. GLOBOCAN 2008 vl. 2, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 10 [DB/OL]. Lyon: International Agency for Research on Cancer, 201 012012-02-01]. http: //globocan. iarc. fr.
  • 7全国肿瘤防治研究办公室,全国肿瘤登记中心,卫生部疾病预防控制局.2010中国肿瘤登记年报(中国肿瘤登记地区2007年肿瘤发病死亡)[M].北京:军事医学科学出版社,2011:1-14.
  • 8Matsumoto J,Minami T,Takami M,et al. A case resect- able hepatic metastases of breast cancer {ollowing intrahe- patic arterial chemotherapy[J]. Gan To Kagaku Ryoho, 1996,23(11) :1542-1545.
  • 9Fumoleau P,Delgado FM,Delozier T, et al. Phase Ⅱ trial of weekly intravenous vinorelbine in first-line advanced breast cancer chemotherapy[J]. J Clin Oncol, 1993, 11 (7) : 1245-1252.
  • 10Terenziani M, Demicheli R, Brambilla C, et al. Vinorel bine: an active, non cross resistant drug in advanced breast cancer. Results from a phase Ⅱ study[J]. Breast Cancer Res Treat,J996,39(3):285-291.

共引文献382

同被引文献15

引证文献2

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部